BACKGROUND This article discusses a case involving a 63-year-old man with non-small cell lung cancer,who was treated with a combination of chemotherapy and immunothe-rapy.The patient was treated with five cycles of ch...
This editorial comments on the review by Da Silva et al,published in the World Journal of Clinical Oncology which focuses on the molecular perspectives of lung cancer.With the rapid development of molecular technology...
This letter provides a review of the report by Peng et al on a unique case of non-small cell lung cancer(NSCLC),specifically lung adenocarcinoma,featuring reactive oxygen species proto-oncogene 1-receptor(ROS1)co-muta...
supported by the National Natural Science Foundation of China(82388102,82373416,and 81602939);Beijing Natural Science Foundation(L234002,and Z240013);Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences(2021-I2M-5-002);Noncommunicable Chronic Diseases-National Science and Technology Major Project(2023ZD0501900).
Globally,lung cancer is the most prevalent cancer(11.4%of all cancers)and the leading cause of cancer deaths(18%of all cancers)[1],[2].With one-fifth of the global population,China is a top contributor to the lung can...
supported by Jiangxi Provincial International Science and Technology Cooperation Project(Nos.20203BDH80W010 and 20232BBH80012);the National Natural Science Foundation of China(Nos.82160410 and 81860379);Foundation of Jiangxi Provincial Department of Science and Technology(No.20212ACB206018);Key Research and Development Program of Jiangxi Province(No.20223BBG71009)。
Accurate determination of lung cancer margins at the molecular level is of great significance to determine the optimal extent of resection during surgical operation and reduce the risk of postoperative recurrence.In t...
National Natural Science Foundation of China,Grant/Award Numbers:92059203,82173386;National Key R&D Program of China,Grant/Award Number:2023YFF0723500;Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences,Grant/Award Number:2021RU002;Medical and Health Science and Technology Innovation project,Grant/Award Number:2021-I2M-002;Beijing Nova Program,Grant/Award Number:20230484314;Innovation Fund for Excellent PhD student of Peking University Health Science Center,Grant/Award Number:2022-58。
Background:Recurrence and metastasis remain significant challenges in lung adenocarcinoma(LUAD)after radical resection.The mechanisms behind the recurrence and metastasis of LUAD remain elusive,and deregulated cellula...
BACKGROUND This manuscript describes the first known cases of sick sinus syndrome(SSS)associated with the use of anlotinib in non-small cell lung cancer patients,highlighting the need for increased vigilance and cardi...
Lung cancer is among the most prevalent cancers and has the highest mortality rate globally.The diagnosis,pathohistological classification,and molecular testing of lung cancer primarily rely on tissue biopsy or surgic...
supported by the China Postdoctoral Science Foundation(2023M742119);the National Natural Science Foundation of China(82403395,82373319,and 82102766);the Natural Science Foundation of Shandong Province(ZR2024QH219);the National Key Clinical Program on Oncology;the Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Special Project(23Y11908600)。
Patients with non-small cell lung cancer(NSCLC)harboring epidermal growth factor receptor(EGFR)mutations show a notable response to tyrosine kinase inhibitor(TKI)treatment.However,almost all patients eventually develo...
Background:Cancer patterns in China are becoming similar to those in the United States(US).Comparing the recent cancer profiles,trends,and determinants in China and the US can provide useful reference data.Methods:Thi...